SynthesisInternational journal of cancer2026
Blood-Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations.
Synthesis in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early detection of colorectal cancer (CRC) via population-based screening programs can reduce incidence and mortality. Current screening approaches are limited by cost, accessibility, compliance, and colonoscopy capacity. Blood-based screening of circulating tumor (ct) DNA may resolve some of these limitations. This systematic review evaluated the screening potential of blood-based ctDNA assays in asymptomatic screening populations. We systematically searched the PubMed database (final search June 20th, 2025) for studies detecting advanced adenomas (AAs) or CRC in asymptomatic cohorts, where a blood-based ctDNA assay had been evaluated with data on specificity, sensitivity, and/or AUC at early stages of disease. Newcastle-Ottowa scale was used for quality assessment. Only 20 studies of 454 unique hits met our inclusion criteria. Of these, 12 studies used assays targeting specific DNA alterations, while the remaining 8 studies used complex assays. Generally, comprehensive assays such as Shield, ColonSecure, and FMBT-CRC had the best performance for early-stage CRC detection with sensitivities of 71%-85% and specificities of 88%-90%. Despite being tested in a small cohort, the Coloscape assay was the only assay to reach sufficient AA detection with 59% sensitivity and 92% specificity. None of the reviewed ctDNA assays demonstrated sufficient sensitivities for both AA and early-stage CRC detection to be considered future screening tools. Screening tools based on ctDNA assays have not proved superior to fecal-based immunochemical test (FIT) yet. Future studies need to test ctDNA screening tools in large, prospective, asymptomatic cohorts emphasizing AA, and early-stage CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.